Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety, pharmacokinetics, and pharmacodynamics of the investigational compound JNJ-56022473 in systemic lupus erythemato…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• JNJ-56022473

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lupus Erythematosus, Systemic | Phase 1 | Status: WITHDRAWN